Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.53 |
| ▸ | TTR | P02766 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3888099 | 0.92 | HPGD (0.61) | HPGDLMNAMEN1KMT2AKDM4E | |
| SCHEMBL6205843 | 0.87 | POLB (0.65) | HPGDLMNAMEN1KMT2AKDM4E | |
| SCHEMBL3761131 | 0.85 | CA12 (0.57) | HPGDLMNAMEN1KMT2AKDM4E | |
| SCHEMBL2705369 | 0.85 | CA12 (0.57) | HPGDLMNAMEN1KMT2AKDM4E | |
| SCHEMBL8144109 | 0.85 | PLA2G10 (0.59) | HPGDLMNAMEN1KMT2AKDM4E | |
| SCHEMBL2732044 | 0.85 | MEN1 (0.58) | HPGDLMNAMEN1KMT2AKDM4E | |
| SCHEMBL3889931 | 0.84 | MAOB (0.54) | HPGDLMNAMEN1KMT2APOLB | |
| SCHEMBL11187836 | 0.84 | GSK3B (0.58) | HPGDLMNAMEN1KMT2AKDM4E | |
| SCHEMBL4551075 | 0.84 | MEN1 (0.64) | HPGDLMNAMEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL8144384 | 0.84 | PLA2G10 (0.58) | HPGDLMNAMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046736-B1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20180334430-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2018-11-22 | — | — | US | disclosed |
| US-9873667-B2 | Arylsulfanyl compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873667-B2 | Arylsulfanyl compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-8841327-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| US-8841327-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| EP-1944303-B1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROCYCLE AND FUNGICIDE CONTAINING THE SAME | EISAI R&D MAN CO LTD (JP) | 2013-08-21 | — | — | EP | disclosed |
| US-8507530-B2 | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8507530-B2 | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8507530-B2 | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| WO-2008014430-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008014430-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070015757-A1 | Novel Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | US | disclosed |
| WO-2005058845-A2 | NOVEL GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2005-06-30 | — | — | WO | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | HPGD 21/4885LMNA 2677/4885MEN1 982/4885 |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | GPI, ERG28, MAN2A1 | HPGD 2551/4885LMNA 2506/4885MEN1 2913/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | HPGD 13/4885LMNA 2573/4885MEN1 1308/4885 |
| US-20070015757-A1 | Novel Glucagon Antagonists/Inverse Agonists | GLP1R, GCGR, GIPR | HPGD 2518/4885LMNA 4123/4885MEN1 1961/4885 |
| US-20180334430-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | ABCB7, ABCB4, PAICS | HPGD 1251/4885LMNA 753/4885MEN1 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.